JPRN-UMIN000017284尚未招募未知
Pharmacokinetics of Tolvaptan:Influence of portal hypertension - Pharmacokinetics of Tolvaptan:Influence of portal hypertension
Juntendo University Nerima Hospital Department of Gastroenterology0 个研究点目标入组 40 人开始时间: 2015年4月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Hepatic encephalopathy (2)Hepatocellular carcinoma vascular invasion is observed in hepatic vein trunk, portal vein trunk,or inferior vena cava (3)NYHA Class 3 or more of heart disease (4)anuria, urinary tract stenosis, stones, or tumors urinary excretion. (5)Patients with cerebrovascular disease within 30 days. (6)Patients with following laboratory values can be seen:Hb<8.0g/dl,T-bil> 4.0mg/dl,Cre>2.0mg/dl,serum Na>147mEq/l,serum K>5.5mEq/l
研究者
相似试验
已完成
不适用
The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgerypatients who receive off-pump coronary artery bypass surgeryJPRN-UMIN000011039Juntendo University Faculty of Medicine100
已完成
Unknown
Effect of early administration of tolvaptan on pleural effusion post-hepatectomyCases of hepatectomyJPRN-UMIN000051266Shiga Medical University136
已完成
不适用
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
招募中
不适用
Efficasy and safety of tolvaptan in patients undergoing peritoneal dialysis with heart failure despite the standard treatment with conventionalJPRN-UMIN000008712Division of Kidney and Hypertension, the Jikei University School of Medicine40
尚未招募
不适用
A study of Tolvaptan to investigate the pharmacokinetics and diuretic effectcongestive heart failureJPRN-UMIN000006726Kanagawa Children's Medical Center10